ArticleFrontiers in pharmacology2022
The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Impact of national volume-based procurement on physicians' antimicrobial prescribing behaviours: an interrupted time series analysis of 1200 prescriptions in a tertiary hospital.Annals of medicine · 2026Article
- Article
- Drug price trends, regional disparities, and supply shortages under China's National Volume-Based Procurement: a nationwide analysis (2018-2024).BMC health services research · 2026Article
- Analysis of the impact of national centralized volume-based procurement drug policy on the market dynamics of tuberculosis drugs.BMC health services research · 2026Article
- Dynamic evaluation and continuous improvement model of pharmaceutical administration based on DPSIR-TOPSIS.BMC health services research · 2026Article
- Mortality trends and influencing factors of mental disorders among urban and rural residents in China between 2009 and 2021: a longitudinal study with projections to 2030.Frontiers in public health · 2026Article
- The impacts of the national volume-based procurement policy on the chronic disease medication market in China's public hospitals: a case study of medications for diabetes.BMC health services research · 2025Article
- Pharmaceutical expenditure changes under the volume-based procurement policy: Effects and influencing factors.PloS one · 2025Article
- The impacts of diagnosis-intervention packet payment on inpatient medical costs for hematologic malignancies and solid tumors: evidence from a retrospective study in China.Frontiers in public health · 2025Article
- Increased consumption of cardiovascular drugs under volume-based procurement (VBP) policy: demand release or assessment inducing?Health research policy and systems · 2024Article
- Atezolizumab plus bevacizumab and chemotherapy versus bevacizumab plus chemotherapy for metastatic cervical cancer: a cost-effectiveness analysis.Frontiers in pharmacology · 2024Article
- Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.Frontiers in pharmacology · 2024Article
- Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China.Frontiers in public health · 2024Article
- The impact of Chinese volume-based procurement on pharmaceutical market concentration.Frontiers in pharmacology · 2024Article
- The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.International journal for equity in health · 2023Article
- Improving access to medicines and beyond: the national volume-based procurement policy in China.BMJ global health · 2023Review
- Impact of China's National Centralized Drug Procurement Policy on pharmaceutical enterprises' financial performance: a quasi-natural experimental study.Frontiers in public health · 2023Article
- The Influence of Diagnosis Intervention Packet Policy Intervention on Medication Structure and Drug Cost of Elderly Hypertensive Inpatients in China: A Multicenter Interrupted Time-Series Analysis.Risk management and healthcare policy · 2023Article
- Does China's centralized volume-based drug procurement policy facilitate the transition from imitation to innovation for listed pharmaceutical companies? Empirical tests based on double difference model.Frontiers in pharmacology · 2023Article
- Perceptions of the benefits of the basic medical insurance system among the insured: a mixed methods research of a northern city in China.Frontiers in public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.